Catalent installing new tableting, encapsulation equipment as part of $40m investment

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags Catalent

Catalent is installing new equipment to increase its formulation capabilities and capacity to manufacture controlled-release tablets and capsules.

The $40m investment will see the addition of a laser drill for osmotic drug delivery and stick pack dosage manufacturing capabilities at the company’s Winchester, KY-based facility.

According to the company, it also will increase its roller compaction and fluid bed capacity – and an automated bottling line is currently being installed.

Additionally, a new spray dryer will provide commercial scale-up capacity for projects progressing from early-stage development. This will enable tech transfer of projects from Catalent’s development sites, including San Diego, CA and Nottingham, UK, according to the company.

Equipment validation is expected over the coming months.

Formulation and supply services

In related news, Catalent recently announced that it has successfully provided formulation and supply services for MGB Biopharma’s Phase II clinical trial materials.

Catalent and MGB Biopharma have been working together to formulate and manufacture MGB Biopharma’s leading candidate, MGB-BP-3, an orally-dosed drug for the treatment of Clostridium difficile-associated diarrhea (CDAD).

Also earlier this month, Catalent expanded its hot melt extrusion (HME) capabilities​ at its drug development center of excellence. Additionally, the company opened​ its 30,000-square-foot Shanghai, China-based clinical supply facility, which is expected to employ up to 100.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

Related suppliers

Follow us

Products

View more

Webinars